Abstract Number: 0299 • ACR Convergence 2025
Interpreting Myositis Autoantibody Line-Blot Immunoassays in Real-World Settings: Implications for Diagnostic Accuracy for Inflammatory Myopathies
Background/Purpose: Idiopathic inflammatory myopathies (IIM) present with diverse clinical features and disease courses. The myositis autoantibody line blot immunoassay (LIA) has advanced IIM diagnostics and…Abstract Number: 2496 • ACR Convergence 2025
Comparing Long-term Outcome Across Systemic Sclerosis Subgroups Using a Multi-Organ Disease Progression Score
Background/Purpose: Evaluating disease modification in systemic sclerosis (SSc) is challenging and requires long term studies. This is especially relevant to limited cutaneous (lc)SSc where severe…Abstract Number: 2245 • ACR Convergence 2025
Add-on of Coronary Artery Calcium Score Significantly Improves the Risk Prediction of Cardiovascular Diseases in Patients with Rheumatoid Arthritis: From a Real-world Cohort Study
Background/Purpose: Cardiovascular diseases (CVD) are the first cause of death in patients with rheumatoid arthritis (RA). The guidelines recommend risk prediction in all RA patients.…Abstract Number: 2023 • ACR Convergence 2025
Isolated Anti-Ro52 Antibody Positivity Is Associated with Increased Cancer Risk and Distinct Malignancy Patterns: A Retrospective Cohort Study from a Single Tertiary Center
Background/Purpose: Anti-Ro52 antibodies are frequently detected in patients with systemic autoimmune rheumatic diseases (SARDs). Emerging evidence suggests a potential link between isolated anti-Ro52 positivity and…Abstract Number: 1665 • ACR Convergence 2025
Comparative Effectiveness of Biologic Versus Conventional Therapy in Uveitis with Systemic Rheumatic Diseases: Real-World Evidence from a Propensity-Matched Cohort
Background/Purpose: Uveitis is a vision-threatening manifestation of systemic rheumatic diseases. While conventional immunosuppressants are typically first-line, biologics are often reserved for refractory cases. Long-term real-world…Abstract Number: 1486 • ACR Convergence 2025
Systemic Lupus Erythematosus and Statins in GLADEL 2.0: Are Cardiovascular Risk Prevention Guidelines Being Followed?
Background/Purpose: Patients (pts) with systemic lupus erythematosus (SLE) have a significantly increased risk of atherosclerotic cardiovascular disease (ASCVD). EULAR recommends a comprehensive assessment and management…Abstract Number: 1158 • ACR Convergence 2025
Clinical and Genetic Features of CTLA-4 Haploinsufficiency : A Prospective Study in China
Background/Purpose: Heterozygous loss-of-function mutations in CTLA4 cause a spectrum of immune dysregulation, characterized by hypogammaglobulinemia, autoimmune cytopenias, and lymphoproliferation, yet penetrance and expressivity remain highly…Abstract Number: 0621 • ACR Convergence 2025
Risk Factors for Pulmonary Manifestations in GLADEL 2.0, a Systemic Lupus Erythematosus Latin American Cohort
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a multisystemic autoimmune disease. Pleuropulmonary (PP) manifestations, including pleural effusion (PE), interstitial lung disease (ILD), pulmonary hypertension (PH), shrinking…Abstract Number: 0516 • ACR Convergence 2025
Association between anti-cytosolic 5′-nucleotidase 1A (anti-cN1A) antibodies and lymphoma in primary Sjögren Disease (SD)
Background/Purpose: There is an unmet clinical need for identification of novel biomarkers of systemic complications and lymphoma in primary Sjögren disease (SD). Anti-cytosolic 5'-nucleotidase 1A…Abstract Number: 0251 • ACR Convergence 2025
Impact of Mepolizumab on Idiopathic Hypereosinophilic Syndromes: Preliminary Analysis of a Monocentric Retrospective Cohort
Background/Purpose: Idiopathic hypereosinophilic syndromes (iHES) are a group of disorders characterized by persistent eosinophilia and eosinophil-mediated organ damage. Mepolizumab, an anti-interleukin-5 monoclonal antibody, has proven…Abstract Number: 2476 • ACR Convergence 2025
Blinatumomab in rapid progressive systemic sclerosis
Background/Purpose: Systemic sclerosis is a severe, potentially fatal disease, characterized by progressive fibrosis of skin and internal organs. Blinatumomab is a bispecific CD3/CD19-T-cell engager (BiTe)…Abstract Number: 2241 • ACR Convergence 2025
RADAR: A Deep Learning Pipeline for Automated Scoring of Joint Damage in Rheumatoid Arthritis Radiographs
Background/Purpose: Rheumatoid arthritis (RA) is a persistent inflammatory disorder inducing joint space narrowing and erosion at both hands and feet. Reading of X-ray images remains…Abstract Number: 2018 • ACR Convergence 2025
Investigating Epidemiology, Clinical associations, and Outcomes of Uveitis: A Retrospective Cohort Study
Background/Purpose: Uveitis is a significant cause of visual impairment in the U.S., with a prevalence of 438 per 100,000 persons [1]. It is anatomically classified…Abstract Number: 1664 • ACR Convergence 2025
Cardiac Sarcoidosis Response to Steroid-Sparing Immunosuppression
Background/Purpose: There are no FDA-approved therapies for cardiac sarcoidosis (CS), a disease associated with high morbidity and mortality. Treatment typically consists of glucocorticoids and off-label…Abstract Number: 1479 • ACR Convergence 2025
Validation of Attention, Memory, and Frontal-Executive Abilities Screening Test (AMFAST) in Systemic Lupus Erythematosus (SLE), a prospective single-center study in The Bronx
Background/Purpose: Up to 80% of Systemic Lupus Erythematosus (SLE) patients experience cognitive dysfunction (CD), which is a top distressing symptom affecting their quality of life.(1)…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 38
- Next Page »